abs236.txt	although	successes	in	cancer	immunotherapy	have	generated	considerableexcitement		this	form	of	treatment	has	been	largely	ineffective	patients	withpancreatic	ductal	adenocarcinoma	(pda)	mechanisms	that	contribute	to	the	poorantitumor	immune	response	pda	are	not	well	understood	here	we	demonstratedthat	cytokine	il35	is	a	major	immunosuppressive	driver	and	potentiatestumor	growth	via	suppression	endogenous	antitumor	t-cell	responses	thegrowth	pancreatic	tumors	mice	deficient	for	was	significantly	reduced	an	analysis	tumor-infiltrating	cells	revealed	role	theexpansion	regulatory	t	cd4+	effector	wealso	detected	robust	increase	both	infiltration	activation	ofcytotoxic	cd8+	suggesting	targeting	may	be	effectivestrategy	convert	from	immunologically	cold	hot	tumor	althoughpda	typically	resistant	anti-pd-1	demonstrated	robustsynergistic	reduction	when	deficiency	combined	withanti-pd-1	these	findings	provide	new	insight	into	function	il35in	pathogenesis	underscore	potentialsignificance	as	therapeutic	target	use	combination	immunotherapyapproaches	deadly	malignancy	immunol	res	6(9)	1014-24	Â©2018aacr
